However, when secreted by tumor associated-dendritic cells (TADCs), CXCL9 can also enhance the expression of the checkpoint molecule ligand programmed death-ligand 1 (PD-L1), thereby attenuating anti-tumor T cell immunity via the PD-1/PD-L1 pathway (28). This evidence concerns the gene CXCL9 and neoplasm.